Reuters logo
BRIEF-AstraZeneca says fostamatinib did not meet study goal
December 13, 2012 / 7:31 AM / 5 years ago

BRIEF-AstraZeneca says fostamatinib did not meet study goal

LONDON, Dec 13 (Reuters) - AstraZeneca PLC : * Top-line results of oskira-4 phase iib study of fostamatinib as a monotherapy

for rheumatoid arthritis * Did not meet second primary goal * All fostamatinib monotherapy doses were inferior to adalimumab monotherapy at

week 24 based on das28

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below